Vir Biotechnology, Inc. (VIR) Stock

Vir Biotechnology, Inc. (VIR) is a Healthcare stock trading at $9.22 (as of 2026-08-20), with a market capitalization of $1.55B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Vir Biotechnology, Inc. develops antibody-based therapeutic and preventive products for infectious diseases, including treatments and prevention programs targeting COVID-19, hepatitis B, influenza A, and HIV. Its pipeline includes Sotrovimab (VIR-7832) and other investigational antibodies such as VIR-2218, VIR-2482, VIR-3434, and VIR-1111, intended for patients at risk of or living with these infections.

Understand Vir Biotechnology, Inc.: how it makes money

Vir Biotechnology develops therapeutic products and antibodies to treat and prevent serious infectious diseases (including COVID-19 under the Xevudy brand, hepatitis B virus, influenza A virus, and human immunodeficiency virus), and it makes money through collaboration, grant, and contract arrangements tied to its development programs.

The profit model is development-driven, where near-term revenue depends on collaboration, grant, and contract funding rather than product sales (and in the latest quarter, all these revenue categories are 0.0B).

Revenue by segment (latest quarter)
Collaboration	$0.0B
Grant	$0.0B
Contract	$0.0B

Business quality (Weak): Segments are represented as revenue categories available in the provided data, and the latest quarter shows 0.0B revenue with a very large operating loss, so the company is best understood as a clinical-development and funding story rather than a revenue-generating business in the period provided.

Bull case

Broad pipeline across multiple infectious diseases: It develops Sotrovimab (VIR-7832) for SARS-CoV-2 infection and prevention (Xevudy), plus programs including VIR-2218 and VIR-3434 for hepatitis B virus, VIR-2482 for influenza A virus prevention, and VIR-1111 for HIV prevention.
Support from major research funders: The company has grant agreements with the Bill & Melinda Gates Foundation and the National Institutes of Health.
Clinical effectiveness signals in the provided metrics: In the provided operating metrics, Objective Response Rate is 45% and Disease Control Rate is 64%.

Bear case

No revenue reported in the latest quarter: For the period 2025-09-30, revenue_b is 0.0B, with Collaboration Revenue, Grant Revenue, and Contract Revenue all at 0.0B.
Very large operating loss in the latest quarter: Operating margin_pct is -72267.9 for the period 2025-09-30 (gross margin is not provided).
Clinical and safety uncertainty: Higher Than or Equal to Grade Three Treatment-Related Adverse Events is 12% in the provided metrics, and the company must still demonstrate safety and efficacy to translate development into revenue.
Workforce reduction suggests financial pressure: Workforce Reduction Percent is 25% and Workforce Reduction Employees is 140 in the provided operating metrics.

Valuation — source: SEC EDGAR (first-party)
Price	$9.22
Market Cap	$1.55B
Price / Book	1.91
Price / Sales	23.74
FCF Yield	-28.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$68.56M
Net Margin	-638.9%
Revenue Growth (YoY)	-101.0%
EPS Growth (YoY)	-3.4%
FCF Growth (YoY)	66.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	0.57 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($161.27M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Marianne De Backer
Employees	408
Country	US
IPO Date	2019-10-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.